All News

ACR20 Podcast

ACR20 - Autoinflammatory & Still's Disease Panel

d Jack Cush, MD

This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.

Read Article
podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

d Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
influenza-156098_640.png

Flu and Tofacitinib

d Kathryn H. Dao, M.D.

Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.

Read Article
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/Bm5rgBPKkH

Links:

Dr. John Cush RheumNow ( View Tweet)
Read more on Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis by Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/yataL7H8X4 https://t.co/JBM8V6OX8J

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Mon

ACR20 - Day 4 Report

d Jack Cush, MD

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
Roundup RHeum ACR

Rheumatology Round-Up with Drs. Kavanaugh & Cush

d Jack Cush, MD

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
sheila RHEUMarampa ( View Tweet)
#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow https://t.co/H9rgSxL6VP
David Liew drdavidliew ( View Tweet)
Which biologic will you use after MTX and TNF failure for RA pts? #acr20 @rheumnow

k dao KDAO2011 ( View Tweet)

Amazing lecture by Dr Jane Salmon for the RRF memorial foundation to honor Dr Shaun Ruddy #ACR20 @HSpecialSurgery @RheumNow the IMPACT study - pregnancy in APS with Certolizumab Therapy https://t.co/A9U11qI7zG
Bella Mehta bella_mehta ( View Tweet)
#ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
Eric Dein ejdein1 ( View Tweet)
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

David Liew drdavidliew ( View Tweet)

Improvement of enthesitis US scores consistent with bDMARD initiation/change 1⃣MASEI and OMERACT scores improved at 3 mo/6mo 2⃣Associated with clinical activity outcomes @RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
David Liew drdavidliew ( View Tweet)
Rheum Now shares Day 3 highlights from #ACR20. https://t.co/xNv1fG97ib https://t.co/Psa8bRqlVh

Links:

Dr. John Cush RheumNow ( View Tweet)
RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q

Links:

Dr. Tina Mahajan drtinamahajan ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.